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naphylaxis  is  a  severe  systemic  allergic  reaction  that  is
apid  in  onset  and  is  potentially  fatal.  Its  severity  varies  in
elation  to  the  affected  organs  and  the  intensity  of  the  dam-
ge  to  these.  The  more  severe  forms  are  associated  with
irway  obstruction  (laryngeal  edema,  severe  bronchocon-
triction)  and/or  vascular  collapse  (anaphylactic  shock).1,2
The  frequency  of  anaphylaxis  ranges  from  0.03%  to  0.95%.
ts  lifetime  can  be  of  up  to  2.6%.  Although  anaphylaxis  occurs
ore  frequently  in  children  and  adolescents,  fatal  cases
re  more  common  in  adults.  Even  though  mortality  rates
re  sub-reported,  it  is  estimated  to  occur  in  0.65--2%  of
evere  anaphylaxis  cases.  Laryngeal  edema  and  cardiovas-
ular  complications  are  the  main  cause  of  death.2--6
Anaphylaxis  can  occur  as  a  consequence  of  immunolog-
cal  and  non-immunological  mechanisms.  In  general,  the
ost  frequent  form  of  anaphylaxis  is  associated  with  IgE-
ediated  hypersensitivity  reactions.  Nevertheless,  aside
rom  the  mechanism  involved  in  the  onset  of  response,
 common  pathophysiological  characteristic  of  anaphylaxis
s  the  degranulation  of  basophils  and  mast  cells,  with  the
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ng  histamine,  leukotrienes  and  prostaglandins.  The  action
f  these  mediators  in  the  skin,  mucous  membranes,  air-
ays,  gastrointestinal  tract,  cardiovascular  system,  and
ther  target  organs,  originates  the  signs  and  symptoms  of
naphylaxis.2,4 The  most  common  causes  of  anaphylaxis
re  medications,  drugs  and  hymenoptera  venoms.  Other
auses  of  anaphylaxis  mediated  by  immunological  mecha-
isms  include  allergen  immunotherapy,  latex,  occupational
llergens,  seminal  ﬂuid,  aeroallergens  and  monoclonal  anti-
odies.  Exercise,  some  physical  factors  (cold,  heat  and
adiation),  ethanol,  opioid  medications  and  contrast  media,
ay  cause  non-immunological  anaphylaxis.  Idiopathic  ana-
hylaxis,  where  it  is  not  possible  to  identify  the  cause,
epresents  over  20%  of  all  anaphylaxis  cases.2--7
Anaphylaxis  is  characterized  by  a  varied  clinical  pre-
entation  and  its  manifestations  include  skin,  respiratory,
cular,  cardiovascular  and  gastrointestinal  symptoms.  Vital
unctions  are  compromised  in  the  most  severe  forms,  and
f  this  occurs  during  the  ﬁrst  minutes  after  the  onset  of  the
eaction,  the  risk  of  death  is  greater.1,2,8,9
Over  90%  of  the  patients  display  skin  symptoms.  Most
pisodes  begin  with  pruritus  and  ﬂushing  and  continue  with
he  progressive  development  of  hives  and/or  angioedema.
yes  and  mucous  membranes  can  acquire  a  congestive-like
spect,  changes  generally  associated  with  intense  itch-
ng,  epiphora  and  rhinorrhea.  Gastrointestinal  symptoms
nclude  abdominal  pain,  nausea,  vomiting,  and  diarrhea.
t  a respiratory  level,  the  symptoms  can  include  tight-
ess  in  the  throat,  dysphagia,  dysphonia,  inspiratory  stridor
asson Doyma México S.A. This is an open access article under the
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and  even  signs  of  asphyxia,  which  is  caused  by  the  gen-
eration  of  laryngeal  edema.  On  the  other  hand,  cough,
dyspnea,  wheezing,  a  feeling  of  tightness  in  the  chest  may
onset  as  a  consequence  of  bronchoconstriction,  which  can
also  cause  hypoxemia  and  cyanosis.  Cardiovascular  man-
ifestations  may  onset  with  tachycardia  and  a  feeling  of
dizziness  or  instability,  and  progress  until  the  loss  of  con-
sciousness.  Peripheral  vasodilatation  and  the  increase  in
vascular  permeability,  characteristics  of  anaphylaxis,  lead
to  hypotension  and  shock,  which  increase  heart  rate  and
reduce  coronary  perfusion.  These  cardiovascular  changes,
in  addition  to  hypoxemia  related  to  the  obstruction  of
the  airways,  reduce  cardiac  oxygenation  and  may  lead  to
arrhythmias  and  myocardium  necrosis,  which  are  causes  of
cardiac  arrest.  In  some  cases,  anaphylaxis  onset  can  be
abrupt,  like  syncope,  or  even  cause  sudden  death.  Other
manifestations  that  may  occur  during  anaphylaxis  are;  dis-
orientation,  anxiety,  seizures  and  profuse  sweating.1,2,8--11
Approximately  20%  of  patients  presenting  anaphylaxis
may  suffer  biphasic  reactions.  In  these  cases,  the  late  phase
begins  between  1  and  72  h  after  the  initial  phase,  usually
with  similar  clinical  manifestations.  No  clinical  data  has
been  identiﬁed  which  allows  the  prediction  of  risk  of  late
reactions  in  a  trustworthy  manner.  However,  the  patients
who  present  severe  initial  reactions  may  have  a  greater  risk
of  suffering  biphasic  reactions.1,8,9
Diagnosis
The  diagnosis  of  anaphylaxis  is  fundamentally  clinical.  Clin-
ical  history  constitutes  the  most  important  tool  in  the
identiﬁcation  of  a  patient  who  is  suffering  from  anaphylaxis
and  it  is  also  of  great  help  to  identify  its  cause.  In  addition
to  the  detailed  description  of  signs  and  symptoms  present  in
the  patient,  it  is  important  to  obtain  information  about  the
moment  of  onset  of  the  reaction,  medication  used  to  treat
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Table  1  Clinical  criteria  for  anaphylaxis  diagnosis.
The  probability  of  anaphylaxis  in  a  patient  is  high  when  at  least  on
1.  Acute  onset  (from  a  few  minutes  to  a  few  hours)  of  a  condition  
hives, itching  or  generalized  ﬂushing/edema  of  the  lips,  tongue  
AND AT  LEAST  ONE  OF  THE  FOLLOWING
a.  Compromised  breathing  (ex.  dyspnea,  wheezing  [bronchospasm
b. Arterial  hypotension  or  symptoms  associated  with  circulatory  co
2. Two  or  more  of  the  following  situations  which  occur  rapidly  afte
hours):
a. Affectation  of  the  skin  and/or  mucous  (ex.  hives,  itching  or  gen
b. Compromised  breathing  (ex.  dyspnea,  wheezing  [bronchospasm
c. Arterial  hypotension  or  symptoms  associated  with  circulatory  co
d. Persistent  gastrointestinal  symptoms  (ex.  crampy  abdominal  pai
3. Hypotension  after  exposure  to  a  known  allergen  for  this  patient
a. Children:  low  systolic  BP  (according  to  age)  or  a  reduction  great
b. Adults:  systolic  BP  less  than  90  mm  Hg  or  a  decrease  greater  tha
Source:  Adapted from Sampson H.A., et al. J Allergy Clin Immunol 200
PEF, peak expiratory ﬂow; BP, blood pressure.
*Low systolic blood pressure in children is deﬁned as less than 70 mm H
Hg + 2× years of age, in children from 1 to 10 years old, and less than 9189
t,  the  duration  of  the  episode  and  exposure  to  allergens  or
otential  triggers.  Whenever  possible,  we  ought  to  question
he  people  who  witnessed  the  event.9--13
Useful  clinical  criteria  have  been  established  for  the  diag-
osis  of  anaphylaxis,  which  are  listed  in  Table  1. With  the
roper  use  of  these  criteria,  it  is  possible  to  identify  over
5%  of  anaphylaxis  cases.1
During  the  clinical  evaluation  of  the  patient,  we  should
lways  consider  other  conditions  which  may  occur  with  sim-
lar  signs  and  symptoms  to  those  of  anaphylaxis.  Differential
iagnoses  include:  vasovagal  reactions,  anxiety,  myocardial
ysfunction,  pulmonary  embolism,  foreign  body  aspiration,
oisoning,  hypoglycemia,  convulsive  disorders,  urticaria  and
ngioedema,  hereditary  angioedema  and  asthma.  Although
rticaria  and  angioedema  may  occur  up  to  90%  of  anaphy-
axis  episodes,  when  it  occurs  without  affecting  other  organs
r  systems,  it  does  not  correspond  to  anaphylaxis  cases.9--13
Serum  tryptase,  plasmatic  histamine  and  histamine
etabolites  in  urine  (methyl-histamine)  may  be  useful  to
onﬁrm  an  anaphylaxis  diagnosis.  The  best  time  for  its
easurement  after  the  onset  of  the  anaphylaxis  episode  is
etween  1  and  6  h  for  serum  tryptase,  from  10  min  to  1  h
or  histamine  and  during  the  ﬁrst  24  h  for  methyl-histamine.
evertheless,  these  studies  are  not  always  available  and  the
dministration  of  the  treatment  should  not  be  delayed.1,10--14
On  the  other  hand,  as  a  part  of  the  attention  in  the
mergency  service,  in  moderate  to  severe  anaphylaxis,  it  is
onvenient  to  perform  a  complete  blood  count,  metabolic
anel,  arterial  blood  gas,  and  chest  x-rays  in  order  to  assess
he  patient’s  general  condition  as  well  as  rule  out  other
iagnoses.9,11--13,15reatment
imely  treatment  considerably  reduces  the  risk  of  mortality
n  patients  with  anaphylaxis.  Management  ought  to  begin
e  of  the  following  three  criteria  are  met:
characterized  by  affectation  of  the  skin  and/or  mucous  (ex.
and/or  uvula)
],  stridor,  reduced  PEF,  hypoxemia)
mpromise  (e.g.  hypotonia  [collapse],  syncope,  incontinence)
r  exposure  to  a  probable  allergen  (a  few  minutes  to  a  few
eralized  ﬂushing/edema  of  the  lips,  tongue  and/or  uvula)
],  stridor,  reduced  PEF,  hypoxemia)
mpromise  (e.g.  hypotonia  [collapse],  syncope,  incontinence)
n,  vomiting)
 (a  few  minutes  to  a  few  hours)
er  than  30%  in  the  systolic  BP
n  30%  in  the  systolic  BP
6;117: 391-7.
g in children from 1 month to 1 year old; less than 70 mm.
0 mm Hg in patients from 11 to 17 years old.
190  A.  Arias-Cruz
Table  2  Drugs  indicated  in  the  treatment  of  anaphylaxis.
Drug  Dose  and  administration
Epinephrine  •  Adults:  0.3--0.5  mg  (0.3--0.5  mL  of  a  1:1000  solution)  intramuscular.
• Children:  0.01  mg/kg  (0.01  mL/kg  of  a  1:1000  solution)  intramuscular  (maximum  dosage  0.3  mg).
• The  dose  can  be  repeated  every  5--15  min  if  necessary  (depending  on  response).
• Intravenous  administration:  only  if  there  is  no  response  to  epinephrine  administered
intramuscular.  It  should  be  administered  slowly  and  diluted  1:10,000,  through  an  infusion  pump
and only  by  trained  medical  personnel.
Antihistamines  •  H1  Antagonists.  Diphenhydramine:  25--50  mg  in  adults;  1  mg/kg  (up  to  50  mg)  in  children.
Intravenous  administration  should  be  slow.  Intramuscular  administration  is  an  alternative.  Oral
intake can  be  considered  in  less  serious  cases.
• H2  antagonists.  Ranitidine:  50  mg  in  adults  and  1  mg/kg  (up  to  50  mg)  in  children.  IV
administered  over  5  min,  diluted  in  a  glucose  solution  at  5%.
Corticosteroids  •  Methylprednisolone:  1--2  mg/kg/day  or  an  equivalent  dose  of  hydrocortisone  (4--8  mg/kg).
Intravenous  administration  every  6  h.  Oral  prednisone  0.5  mg/kg;  useful  in  less  serious  cases.
Bronchodilators  •  Beta-2  agonist.  Nebulized  salbutamol,  2.5--5  mg  in  3  mL  of  saline  solution  or  2--6  puffs  of  MDI.
Repeat as  necessary  (every  20  min).
Crystalloid  solutions  •  0.9%  saline  solution.  Adults:  0.5--1  L  in  the  ﬁrst  5--10  min.  Some  cases  may  require
administration  of  up  to  7  L  in  total.  Children  may  receive  up  to  30  mL/kg  in  the  ﬁrst  hour.
Vasopressors  •  Dopamine:  400  mg  in  500  mL  of  glucose  solution  at  5%;  infuse  at  a  dosage  of  20  g/kg/min.  Use
only when  there  is  no  adequate  response  to  treatment  with  epinephrine  intramuscular  and
infusion with  intravenous  ﬂuids,  or  if  the  hypotension  is  severe.
Glucagon  •  Initial  dosage:  1--5  mg  in  adults  and  20--30  g/kg  (maximum  dosage  of  1  mg)  in  children.
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vIntravenous  administration  over
ith  an  evaluation  and  the  maintenance  of  airways,  venti-
ation  and  circulation.1,9--15
If  the  patient  meets  clinical  criteria  for  an  anaphylaxis
iagnosis,  epinephrine  should  be  administered  immediately.
he  recommended  dose  is  0.01  mg/kg  (maximum  dose  of
.3  mg  in  children  and  0.5  mg  in  adults)  administered  intra-
uscular  in  the  antero-lateral  area  of  the  thigh,  repeating
very  5--15  min  if  necessary  (Table  2).  Intravenous  adminis-
ration  is  an  option  in  patients  with  severe  hypotension  or
ardiovascular  collapse  who  do  not  respond  to  treatment
ith  intramuscular  epinephrine  and  intravenous  ﬂuids.  Nev-
rtheless,  due  to  the  risks  of  lethal  arrhythmia,  the  latter
orm  of  administration  should  be  considered  only  when  con-
inuous  cardiac  monitoring  is  possible.1,2,4,8--16
The  need  for  therapeutic  procedures  in  addition  to  the
dministration  of  epinephrine  in  the  patient  with  anaphy-
axis  should  be  individualized  according  to  the  present
ituation  in  each  particular  case  and  the  response  to  treat-
ent. 9--16 These  measures  include:
 Monitoring  of  vital  signs  and  surveillance  of  the  level  of
consciousness.
 Supine  position  with  elevation  of  lower  extremities  in  case
of  hypotension.
 Canalization  of  the  peripheral  venous  way.
 Ventilatory  assistance  with  a  bag-valve-mask  device.  Con-
sider  endotracheal  intubation  or  cricothyroidotomy  if  the
severity  of  the  episode  requires  it.
 Administration  of  oxygen  (6--8  L/min).  Pulse  oximetry  is  a
guide  to  determine  the  oxygen  requirements.
 Fluid  resuscitation.  The  use  of  crystalloid  solutions
(normal  saline)  is  preferred  (Table  2).  Colloid  volume
expanders  are  an  option,  but  they  have  not  shown  be
t
a
I
sn.  Maintenance  dosage:  intravenous  infusion  (5--15  g/min).
better  than  crystalloid  solutions  for  the  treatment  of
hypotension  in  anaphylaxis.
 Antihistamines.  They  are  second  line  drugs  in  anaphylaxis.
Antihistamines  may  be  useful  for  the  treatment  of  cuta-
neous  and  mucous  membranes  symptoms.  In  anaphylaxis,
it  is  recommended  the  use  of  a  combination  of  H1  and  H2
antagonists  (Table  2).
 Inhaled  beta-2  adrenergic  agonists,  if  there  is  bron-
chospasm  resistant  to  epinephrine  (Table  2).
 Corticosteroids.  Although  they  are  not  useful  in  the  early
phase  of  anaphylaxis,  they  can  potentially  reduce  the  risk
of  late  phase  reactions  (Table  2).
 In  cases  of  hypotension  refractory  to  treatment  with
intravenous  ﬂuids  and  epinephrine,  The  administration
of  vasopressors  should  be  considered,  with  the  aim  of
maintaining  arterial  pressure  above  90  mm  Hg.  Continuous
hemodynamic  monitoring  is  necessary  (Table  2).
 Glucagon  is  an  alternative  in  patients  who  are  undergo-
ing  treatment  with  beta-adrenergic  blockers  and  do  not
respond  to  treatment  with  epinephrine  (Table  2).
 Vasopressors.  If  epinephrine  injections  and  ﬂuid  resusci-
tation  fail  to  alleviate  hypotension,  vasopressors  (such  as
dopamine)  should  be  administered  (Table  2).
 If  the  patient  presents  cardiopulmonary  arrest,  life  sup-
port  maneuvers  should  be  applied  and  the  patient  should
be  transferred  to  an  intensive  care  unit,  if  necessary.
Considering  the  possibility  of  late  reactions,  an  obser-
ation  period  is  recommended  after  the  early  phase,  even
hough  the  symptoms  may  have  disappeared  with  the  initial
ttention.  The  observation  periods  should  be  personalized.
n  most  cases,  a  4--6  h  observation  period  in  emergency
ervices  is  reasonable.  However,  in  patients  with  severe
FN
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symptoms  or  refractions  to  the  treatment,  the  observation
period  should  be  longer.  The  need  of  hospitalization  should
be  considered  in  cases  of  respiratory  or  cardiovascular
compromise  which  puts  the  patient’s  life  at  risk,  anaphy-
laxis  refractory  to  the  initial  treatment,  late  reactions,  and
patients  with  a  signiﬁcant  risk  of  severe  complications  due
to  pre-existing  cardiac  or  pulmonary  diseases.1,8--16
Discharge recommendations
Discharge  recommendations  for  a  patient  who  has  suffered
an  anaphylaxis  episode  should  include:
1.  A  prescription  of  self-administered  epinephrine  in  case  of
a  new  episode  of  anaphylaxis.  The  use  of  auto-injector
devices  is  recommended  whenever  possible.
2.  Provide  a  written  emergency  plan  guiding  the  patient  on
the  steps  to  take  in  case  of  onset  of  anaphylaxis  symp-
toms.
3.  Instructions  and  enough  information  on  the  nature  of
their  problem  should  be  provided,  as  well  as  how  to  avoid
exposure  to  allergens  or  potential  triggers.
4.  Refer  the  patient  to  an  allergist  for  his/her  study  and  pos-
sible  identiﬁcation  of  the  speciﬁc  cause  of  anaphylaxis,
as  well  as  to  evaluate  the  possibility  of  a  desensitization
treatment  or  speciﬁc  allergen  immunotherapy.9--16
Conclusions
Anaphylaxis  is  a  systemic  reaction,  it  is  life-threatening  and
it  has  a  rapid  onset.  The  most  frequent  triggers  are  medi-
cations,  foods  and  hymenoptera  venom.  Diagnosis  is  based
on  clinical  criteria.  Clinical  manifestations  include  skin,
respiratory,  cardiovascular  and  gastrointestinal  signs  and
symptoms.  Epinephrine  (intramuscular)  is  the  ﬁrst  choice
of  treatment  and  should  be  administered  as  soon  as  the
anaphylaxis  diagnosis  is  made.  Treatment  additional  to  the
epinephrine  will  depend  on  the  clinical  manifestations  of
each  case.  The  patient’s  observation  period  after  the  atten-
tion  of  the  early  phase  should  be  individualized  according  to
the  severity  of  the  anaphylaxis.  At  the  moment  of  hospital
discharge,  self-administration  of  epinephrine  should  always
be  prescribed  for  all  patients  who  suffered  anaphylaxis.  It  is
essential  to  provide  a  written  action  plan  in  case  of  future
events  of  anaphylaxis  and  to  refer  the  patient  to  an  allergist
for  long-term  attention.Conﬂict of interest
The  author  has  no  conﬂicts  of  interest  to  declare.
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